{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:12:16Z","timestamp":1790248336189,"version":"4.1.0"},"reference-count":23,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Allergic rhinitis is a highly prevalent inflammatory disease that significantly impairs sleep, daily functioning and quality of life, with symptoms increasingly amplified by environmental changes such as prolonged pollen seasons and urban pollution. Despite effective therapies, many patients remain poorly controlled due to delayed diagnosis, inappropriate self-selection of over-the-counter medications, limited adherence and incorrect intranasal technique. The fixed-dose intranasal combination of mometasone furoate and olopatadine addresses these gaps by uniting rapid antihistaminic, mast-cell stabilizing effects with potent, sustained anti-inflammatory activity. Clinical trials demonstrate superior improvement of nasal and ocular symptoms, faster onset of action, and favourable long-term safety compared with monotherapies. Its single-device formulation may enhance adherence and reduce inappropriate polypharmacy, offering a practical, guideline-aligned option for optimizing management of allergic rhinitis and mitigating risks associated with patient self-treatment.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-advances-in-the-management-of-allergic-rhinitis-clinical-relevance-of-the-mometasone-furoate-olopatadine-association-and-the-challenge-of-patient-self-diagnosis-and-se<\/jats:p>","DOI":"10.7573\/dic.2026-2-5","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:35:46Z","timestamp":1779284146000},"page":"1","source":"Crossref","is-referenced-by-count":1,"title":["Advances in the management of allergic rhinitis: clinical relevance of the mometasone furoate\u2013olopatadine association and the challenge of patient self-diagnosis and self-treatment"],"prefix":"10.7573","volume":"15","author":[{"given":"Maria","family":"D\u2019Amato","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0560hqd63","id-type":"ROR","asserted-by":"publisher"}],"name":"Ospedale Monaldi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"D\u2019Amato","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05290cv24","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Naples Federico II"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. D\u2019Amato G, Chong-Neto HJ, Monge Ortega OP, et al. The effects of climate change on respiratory allergy and asthma induced by pollen and mold allergens. Allergy. 2020;75(9):2219\u20132228. https:\/\/doi.org\/10.1111\/all.14476 DOI: 10.1111\/all.14476","DOI":"10.1111\/all.14476"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. D\u2019Amato G, Murrieta-Aguttes M, D\u2019Amato M, Ansotegui IJ. Pollen respiratory allergy: is it really seasonal? World Allergy Organ J. 2023;16(7):100799. https:\/\/doi.org\/10.1016\/j.waojou.2023.100799 DOI: 10.1016\/j.waojou.2023.100799","DOI":"10.1016\/j.waojou.2023.100799"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Baldwin CM, Scott LJ. Mometasone furoate: a review of its intranasal use in allergic rhinitis. Drugs. 2008;68(12): 1723\u20131739. https:\/\/doi.org\/10.2165\/00003495-200868120-00009 DOI: 10.2165\/00003495-200868120-00009","DOI":"10.2165\/00003495-200868120-00009"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999;104(4 Pt 1):S150\u2013S158. https:\/\/doi.org\/10.1016\/s0091-6749(99)70311-8 DOI: 10.1016\/S0091-6749(99)70311-8","DOI":"10.1016\/S0091-6749(99)70311-8"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Paoletti G, Giua C, Marti A, et al. ARIA-Italy managing allergic rhinitis and asthma in a changing world: the role of the pharmacist. World Allergy Organ J. 2025;18(5):101055. https:\/\/doi.org\/10.1016\/j.waojou.2025.101055 DOI: 10.1016\/j.waojou.2025.101055","DOI":"10.1016\/j.waojou.2025.101055"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Lim L, Lipari M, Kale-Pradhan P. Intranasal olopatadine-mometasone in the treatment of seasonal allergic rhinitis. Ann Pharmacother. 2023;57(5):570\u2013578. https:\/\/doi.org\/10.1177\/10600280221124230 DOI: 10.1177\/10600280221124230","DOI":"10.1177\/10600280221124230"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Onrust SV, Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs. 1998;56(4): 725\u2013745. https:\/\/doi.org\/10.2165\/00003495-199856040-00018. DOI: 10.2165\/00003495-199856040-00018","DOI":"10.2165\/00003495-199856040-00018"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Kaliner MA, Oppenheimer J, Farrar JR. Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010;31(2):112\u2013119. https:\/\/doi.org\/10.2500\/aap.2010.31.3317 DOI: 10.2500\/aap.2010.31.3317","DOI":"10.2500\/aap.2010.31.3317"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Ohmori K, Hasegawa K, Tamura T, et al. Properties of olopatadine hydrochloride, a new antiallergic\/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809\u2013829. https:\/\/doi.org\/10.1055\/s-0031-1297036 DOI: 10.1055\/s-0031-1297036","DOI":"10.1055\/s-0031-1297036"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Lamb YN. Olopatadine\/mometasone combination nasal spray in allergic rhinitis: a profile of its use. Drugs Ther Perspect. 2020;36:494\u2013501. https:\/\/doi.org\/10.1007\/s40267-020-00778-y DOI: 10.1007\/s40267-020-00778-y","DOI":"10.1007\/s40267-020-00778-y"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019;122(6):630\u2013638.e3. https:\/\/doi.org\/10.1016\/j.anai.2019.03.017 DOI: 10.1016\/j.anai.2019.03.017","DOI":"10.1016\/j.anai.2019.03.017"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Hampel FC, Pedinoff AJ, Jacobs RL, Caracta CF, Tantry SK. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019;40(4):261\u2013272. https:\/\/doi.org\/10.2500\/aap.2019.40.4223 DOI: 10.2500\/aap.2019.40.4223","DOI":"10.2500\/aap.2019.40.4223"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Andrews CP, Mohar D, Salhi Y, Tantry SK. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2020;124(2): 171\u2013178.e2. https:\/\/doi.org\/10.1016\/j.anai.2019.11.007 DOI: 10.1016\/j.anai.2019.11.007","DOI":"10.1016\/j.anai.2019.11.007"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Segall N, Prenner B, Lumry W, Caracta CF, Tantry SK. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2019;40(5):301\u2013310. https:\/\/ doi.org\/10.2500\/aap.2019.40.4233 DOI: 10.2500\/aap.2019.40.4233","DOI":"10.2500\/aap.2019.40.4233"},{"key":"ref14","unstructured":"15. Summary of Product Characteristics (SmPC). Rinoff\u00ae (Mometasone Furoate nasal spray). https:\/\/api.aifa.gov.it\/ aifa-bdf-eif-be\/1.0.0\/organizzazione\/211\/farmaci\/47513\/stampati?ts=RCP. Accessed May 14, 2025."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Lipiec A, Jurkiewicz D. A new therapeutic option in the management of allergic rhinitis. Otolaryngol Pol. 2021;75(5): 1\u20135. https:\/\/doi.org\/10.5604\/01.3001.0015.4556 DOI: 10.5604\/01.3001.0015.4556","DOI":"10.5604\/01.3001.0015.4556"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Kim JS, Stybayeva G, Hwang SH. Efficacy of montelukast-antihistamine combination therapy compared with antihistamine monotherapy in allergic rhinitis: a systematic review and meta-analysis. Clin Exp Otorhinolaryngol. 2025. https:\/\/doi.org\/10.21053\/ceo.2025-00201 DOI: 10.21053\/ceo.2025-00201","DOI":"10.21053\/ceo.2025-00201"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95. https:\/\/doi.org\/10.1038\/ s41572-020-00227-0 DOI: 10.1038\/s41572-020-00227-0","DOI":"10.1038\/s41572-020-00227-0"},{"key":"ref18","unstructured":"19. Bousquet J, Sch\u00fcnemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70\u201380.e3. https:\/\/doi.org\/10.1016\/j. jaci.2019.06.049"},{"key":"ref19","unstructured":"20. Sousa-Pinto B, Bousquet J, Vieira RJ, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI guidelines-2024\u20132025 revision: part I-guidelines on intranasal treatments. Allergy. 2025;81(4):954\u2013976. https:\/\/ doi.org\/10.1111\/all.70131"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Zhang H, Cao Y, Jiang H, Zhou Q, Yang Q, Cheng L. The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases. Clin Transl Allergy. 2025;15(1):e70020. https:\/\/doi.org\/10.1002\/clt2.70020 DOI: 10.1002\/clt2.70020","DOI":"10.1002\/clt2.70020"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Alvarez-Perea A, S\u00e1nchez-Garc\u00eda S, Mu\u00f1oz Cano R, Antol\u00edn-Am\u00e9rigo D, Tsilochristou O, Stukus DR. Impact of eHealth in allergic diseases and allergic patients. J Investig Allergol Clin Immunol. 2019;29(2):94\u2013102. https:\/\/ doi.org\/10.18176\/jiaci.0354 DOI: 10.18176\/jiaci.0354","DOI":"10.18176\/jiaci.0354"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Li L, Wang Z, Cui L, et al. The efficacy of a novel smart watch on medicine adherence and symptom control of allergic rhinitis patients: pilot study. World Allergy Organ J. 2023;16(1):100739. https:\/\/doi.org\/10.1016\/j.waojou.2022.100739 DOI: 10.1016\/j.waojou.2022.100739","DOI":"10.1016\/j.waojou.2022.100739"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/05\/dic.2026-2-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:33:37Z","timestamp":1790246017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/advances-in-the-management-of-allergic-rhinitis-clinical-relevance-of-the-mometasone-furoate-olopatadine-association-and-the-challenge-of-patient-self-diagnosis-and-self-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-2-5","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"dic.2026-2-5"}}